March/April 2024March/April 2024
PAYMENTform_banner200PAYMENTform_banner200
RATES_banner200RATES_banner200
SIGNUP_banner200SIGNUP_banner200
equineSUBSCRIBE_200animationequineSUBSCRIBE_200animation
EC_advertisng_RS200x345EC_advertisng_RS200x345
paykwik al online sportwetten paykasa

First of Its Kind Blood Purification System For Animals

February 7, 2017 | Filed under: Health & Training | Posted by:     

vetMONMOUTH JUNCTION, NJ, January 20, 2017 –  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the marketing launch and commercial availability of the VetResQ™ sorbent cartridge for the United States veterinary market. VetResQ is a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication.

Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents says, “The VetResQ adsorber provides a new and unique treatment for severe inflammation, toxin-mediated disease, and drug intoxication not previously available in the animal health market. VetResQ leverages a similar underlying blood purification technology in our commercialized CytoSorb® device that is approved in the European Union and has been used in more than 20,000 human treatments safely. Whether it is the sick Thoroughbred racehorse or foal suffering from sepsis or toxic shock syndrome, a dog with acute pancreatitis in terrible pain, a cat after being struck by a car, or a dog poisoned from accidentally eating his owner’s pill bottles, the pathophysiology is remarkably similar to what is seen in humans, with a similar lack of available effective therapies. Our target customers are the large academic veterinary hospitals and veterinary practices where services like dialysis are administered.  Although this is a specialized niche market, we are providing this product at the request of many animal care providers and pet owners, with the goal of improving clinical outcomes for our most trusted and loved animal companions.”
VetResQ is capable of reducing a broad range of excessive inflammatory mediators and toxins that could otherwise cause direct tissue injury or serious systemic inflammation that can rapidly lead to instability, organ failure, and death. Some of the relevant substances VetResQ has been shown to remove include:

  • Excessive pro- and anti-inflammatory cytokines (Sepsis and SIRS – systemic inflammatory response syndrome)
  • Bacterial toxins such as Toxic shock syndrome toxin, Staph. aureus alpha-hemolysin, and fungal mycotoxins such as aflatoxin (Sepsis, infection)
  • Pancreatic enzymes (Severe acute pancreatitis)
  • Bilirubin  (Liver failure)
  • Myoglobin (Trauma)
  • Activated complement (Autoimmune diseases)
  • Lipophilic drugs (Accidental drug intoxication)

VetResQ is manufactured in the United States by CytoSorbents Corporation in three different sized cartridges (30mL, 100mL, and 300 mL) for the treatment of cats, dogs, horses and animals of comparable size. VetResQ is compatible with standard hemodialysis, continuous renal replacement therapy (CRRT), and hemoperfusion blood pumps.  VetResQ is available only for veterinary animal usage and is not for human use.

For more information, please visit www.cytosorbents.com/products/VetResQ. 

 
paykwik online sportwetten paykasa